At a glance
A growth-hormone-derived fragment investigated for effects on fat metabolism.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
The literature includes laboratory work and weight-related clinical investigations. Study design, formulation and the size of the observed effect matter more than a general “fat-loss peptide” label.[10][2][3]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of AOD-9604.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 2 mg · 1 source tables
Standard / Gradual Approach (3 mL = ~0.667 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–4 | 300 mcg | 45 units (0.45 mL) |
| Weeks 5–12 | 500 mcg | 75 units (0.75 mL) |
Frequency: Inject once daily subcutaneously (typically in the morning on an empty stomach). This schedule uses the largest practical dilution (3.0 mL) to keep per‑injection units ≥10 for better accuracy. Rotate injection sites (abdomen, thighs, upper arms) to minimize local irritation.
Additional schedule context & duration
Concise summary of the once‑daily regimen.
- Goal: Support reduction of fat mass and enhance fat oxidation over time[1][4].
- Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
- Dose Range: 300–500 mcg daily with gradual titration.
- Reconstitution: 3.0 mL per 2 mg vial (~0.667 mg/mL) for accurate unit measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Suggested daily titration approach.
- Start: 300 mcg daily for Weeks 1–4; increase to 500 mcg for Weeks 5–12 as tolerated.
- Target: 500 mcg daily by Week 5 and maintain through cycle completion.
- Frequency: Once per day (subcutaneous).
- Cycle Length: 8–12 weeks; optional extension to 16 weeks.
- Timing: Morning administration (fasted) is common; rotate injection sites.
Read this protocol on Pep Science → · View cited documents ↓
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide quality.
Injection Technique
General subcutaneous guidance from clinical best‑practice resources[7].
- Clean the vial stopper and skin with alcohol; allow to dry completely[8].
- Pinch a skinfold; insert the needle at 90° (or 45° if very little subcutaneous fat) into subcutaneous tissue[7].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[13].
- Rotate sites systematically (abdomen at least 2 inches from navel, thighs, upper arms) to avoid lipohypertrophy[8].
Materials & quantity planning
Source materials checklist · 2 mg
Plan based on an 8–12 week daily protocol with gradual titration (300 mcg Weeks 1–4, 500 mcg Weeks 5+).
-
Peptide Vials (AOD-9604, 2 mg each):
- 8 weeks ≈ 12 vials
- 12 weeks ≈ 19 vials
- 16 weeks ≈ 26 vials
-
Insulin Syringes (U‑100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- 8 weeks (12 vials): 36 mL → 4 × 10 mL bottles
- 12 weeks (19 vials): 57 mL → 6 × 10 mL bottles
- 16 weeks (26 vials): 78 mL → 8 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- 16 weeks: 224 swabs → recommend 3 × 100‑count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 2 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 04
Research publication
Endocrinology (OUP) — Effects of hGH and AOD9604 on lipid metabolism in obese mice; β‑adrenergic pathway mechanisms (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 06
Source document
Creative Peptides — Peptide stability and shelf life; reconstituted solution storage guidelines (opens in a new tab)www.creative-peptides.com
Back to overview ↑ - 07
- 08
Source document
Olympia Pharmacy — How to administer a subcutaneous injection; site rotation and hygiene (opens in a new tab)www.olympiapharmacy.com
Back to overview ↑ - 10
Source document
Gastroenterology — Drug treatment of the overweight patient; AOD‑9604 RCT summary and clinical efficacy (opens in a new tab)www.gastrojournal.org
Back to overview ↑ - 11
- 12
Source document
DrugBank — AOD9604 drug summary; mechanism of action, bone and metabolic effects (opens in a new tab)go.drugbank.com
Back to overview ↑ - 13
Public health resource
CDC — Vaccine administration: subcutaneous route; no aspiration required (opens in a new tab)www.cdc.gov
Back to overview ↑
COMMUNITY · EXTERNAL FORUM
Discuss AOD-9604 with the community
Explore member conversations and ask questions on glp1chat. Forum posts and listings are not vetted or endorsed by Pep Science, and they are not medical advice or editorial evidence.
Visit the community (opens in a new tab)Continue exploring
Related topics are not interchangeable compounds or formulations.